|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, and Indiana University School of Medicine, Indianapolis, Indiana 46285, USA
Address for correspondence: Michael W. Draper, M.D., Ph.D., Medical Advisor, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 2138, Indianapolis, IN 46285. Voice: 317-276-2756; fax: 317-277-1234. mwd{at}lilly.com Ann. N.Y. Acad. Sci. 997: 373-377 (2003).
Concerns about long-term therapy with HRT have recently highlighted interest in a class of compounds active in the estrogen receptor, but with selectivity in their actions, known as the selective estrogen receptor modulators (SERMs). Tamoxifen is recognized as the first widely marketed SERM, but its selectivity focuses interest on its approved indications: the treatment and prevention of breast cancer. Raloxifene has been approved in most countries of the world for the treatment and prevention of oseoporosis, and it displays a pattern of actions highly matched to the needs and concerns of many postmenopausal women. Further study of current and future SERMs promises to open new vistas in patient-specific management of the field of postmenopausal health.
Key Words: selective estrogen receptor modulator (SERM) • postmenopausal women • hormone replacement therapy (HRT) • raloxifene This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
